<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110693</url>
  </required_header>
  <id_info>
    <org_study_id>CTN 0059</org_study_id>
    <secondary_id>2U10DA013034</secondary_id>
    <nct_id>NCT02110693</nct_id>
  </id_info>
  <brief_title>The Tobacco, Alcohol, Prescription Medication and Other Substances Tool</brief_title>
  <acronym>CTN0059</acronym>
  <official_title>The TAPS Tool: Screen and Brief Assessment Tool Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Friends Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to develop and validate a questionnaire to screen and assess
      adult primary care patients for tobacco, alcohol, prescription drug, and drug use and
      problems related to their use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study examined the accuracy of a substance abuse screening test compared to gold standard measures Participants all received the experimental screening instrument (via self- and tablet computer administration. The order of administration was randomly selected in order to control for an order effect.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview</measure>
    <time_frame>Baseline</time_frame>
    <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic and Statistical Manual-5 (DSM-5) Cannabis Use Disorder Diagnosis Measured With Modified World Mental Health Composite International Diagnostic Interview</measure>
    <time_frame>Baseline</time_frame>
    <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic and Statistical Manual-5 (DSM-5) Cocaine and Amphetamine (Stimulant) Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview</measure>
    <time_frame>Baseline</time_frame>
    <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic and Statistical Manual DSM-5 Diagnosis of Heroin Use Disorder Measured by the The Modified World Mental Health Composite International Diagnostic Interview</measure>
    <time_frame>Baseline</time_frame>
    <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic and Statistical Manual DSM-5 Diagnosis of Tobacco Use Disorder Measured by the Modified World Mental Health Composite International Diagnostic Interview</measure>
    <time_frame>Baseline</time_frame>
    <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Risk Tobacco Use Measured by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)</measure>
    <time_frame>Baseline</time_frame>
    <description>The ASSIST assess lifetime and past 3 month substance use. A score on the Tobacco Scale from 0-3 is low risk, 4-26 is medium risk, and 27 or greater is high risk.The scales range is from 0 (no problem) to 31 (most severe problem).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unhealthy Cannabis Use</measure>
    <time_frame>Baseline</time_frame>
    <description>The Time Line Follow Back Interview measures participant's self-reported number of days of cannabis use in the 30 days prior to the interview. Unhealthy cannabis use is considered 1 or more days of cannabis use in the past 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risky Alcohol Use</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by the Alcohol Use Disorders Identification Test - Consumption Items. High risk on the AUDIT-C is 10 or higher. The higher the score on the AUDIT-C the greater the alcohol problem.The range of scores on the AUDIT-C is from 0 (no problem) to 12 (maximum problem).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarette Smoking Risk</measure>
    <time_frame>baseline</time_frame>
    <description>Measured by the Fagerstrom Test for Nicotine Dependence. The range of scores on the Fagerstrom Test if from 0 (no risk) to 10 (highest risk). High risk is considered a score of 6 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smokeless Tobacco Questionnaire</measure>
    <time_frame>baseline</time_frame>
    <description>Any yes response to smokeless tobacco use reported on the smokeless tobacco questionnaire is considered high risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabis Positive Oral Fluid Test</measure>
    <time_frame>baseline</time_frame>
    <description>Positive Oral Fluid Cannabis testing.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2057</enrollment>
  <condition>Substance Use Disorder</condition>
  <arm_group>
    <arm_group_label>Interviewer and tablet administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviewer and tablet administration of the TAPS Tool</intervention_name>
    <description>All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.</description>
    <arm_group_label>Interviewer and tablet administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary care patients

          -  Able to provide informed consent

        Exclusion Criteria:

          -  inability to comprehend spoken English

          -  inability to self-administer the instrument on the tablet computer due to physical
             limitations

          -  previously enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Schwartz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li-Tzy Wu, Psy.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer McNeely, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chase Brexton Health Services</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MURDOCK Study</name>
      <address>
        <city>Kannapolis</city>
        <state>North Carolina</state>
        <zip>28081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System Ambulatory Care Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>March 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2018</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Substance Use</keyword>
  <keyword>Substance Use Disorder</keyword>
  <keyword>Screening</keyword>
  <keyword>Brief Assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Interviewer Then Tablet Administration</title>
          <description>Interviewer will administer the substance use screening instrument first then self-administration of the same instrument on a tablet computer</description>
        </group>
        <group group_id="P2">
          <title>Tablet First Then Interviewer Administration</title>
          <description>Self-administration on tablet computer of screening instrument first, then interviewer administration of the same instrument.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1026"/>
                <participants group_id="P2" count="1031"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="998"/>
                <participants group_id="P2" count="1002"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>skipped assessment</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interviewer and Tablet Administration of TAPS Tool</title>
          <description>All participants self-administered TAPS Tool on a computer tablet and were administered the TAPS Tool by an interviewer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2,000"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2,000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Missing data (n=1) and refused to answer (n=1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1,998"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2,000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1761"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Participant chose not to answer (n=7)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2,000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="667"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2,000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview</title>
        <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
        <time_frame>Baseline</time_frame>
        <population>Adult primary care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administration</title>
            <description>Interviewer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Self-administration on tablet computer of screening instrument for substance misuse (TAPS Tool).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview</title>
          <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
          <population>Adult primary care patients</population>
          <units>Sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".70" lower_limit=".64" upper_limit=".75"/>
                    <measurement group_id="O2" value=".74" lower_limit=".68" upper_limit=".79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) was tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Alcohol Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensitivity</param_type>
            <param_value>.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.64</ci_lower_limit>
            <ci_upper_limit>.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) was tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Alcohol Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensitivity</param_type>
            <param_value>.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.68</ci_lower_limit>
            <ci_upper_limit>.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic and Statistical Manual-5 (DSM-5) Cannabis Use Disorder Diagnosis Measured With Modified World Mental Health Composite International Diagnostic Interview</title>
        <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
        <time_frame>Baseline</time_frame>
        <population>Adult primary care population</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administration</title>
            <description>Interviewer administration of a substance misuse screening instrument (TAPS Tool)</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Tablet computer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic and Statistical Manual-5 (DSM-5) Cannabis Use Disorder Diagnosis Measured With Modified World Mental Health Composite International Diagnostic Interview</title>
          <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
          <population>Adult primary care population</population>
          <units>Sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit=".63" upper_limit=".79"/>
                    <measurement group_id="O2" value=".70" lower_limit=".62" upper_limit=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were separately tested against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Cannabis Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensitivity</param_type>
            <param_value>.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.63</ci_lower_limit>
            <ci_upper_limit>.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were separately tested against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Cannabis Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensitivity</param_type>
            <param_value>.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.62</ci_lower_limit>
            <ci_upper_limit>.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic and Statistical Manual-5 (DSM-5) Cocaine and Amphetamine (Stimulant) Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview</title>
        <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
        <time_frame>Baseline</time_frame>
        <population>Adult primary care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administration</title>
            <description>Interviewer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Tablet computer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic and Statistical Manual-5 (DSM-5) Cocaine and Amphetamine (Stimulant) Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview</title>
          <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
          <population>Adult primary care patients</population>
          <units>Sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".57" lower_limit=".47" upper_limit=".67"/>
                    <measurement group_id="O2" value=".60" lower_limit=".50" upper_limit=".69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Cocaine and Amphetamine (Stimulant) Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensitivity</param_type>
            <param_value>.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.47</ci_lower_limit>
            <ci_upper_limit>.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were separately tested against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Cocaine and Amphetamine (Stimulant) Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensitivity</param_type>
            <param_value>.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.50</ci_lower_limit>
            <ci_upper_limit>.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic and Statistical Manual DSM-5 Diagnosis of Heroin Use Disorder Measured by the The Modified World Mental Health Composite International Diagnostic Interview</title>
        <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
        <time_frame>Baseline</time_frame>
        <population>Adult primary care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administration</title>
            <description>Interviewer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Tablet computer of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic and Statistical Manual DSM-5 Diagnosis of Heroin Use Disorder Measured by the The Modified World Mental Health Composite International Diagnostic Interview</title>
          <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
          <population>Adult primary care patients</population>
          <units>Sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".66" lower_limit=".53" upper_limit=".77"/>
                    <measurement group_id="O2" value=".66" lower_limit=".53" upper_limit=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Heroin Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>sensivity</param_type>
            <param_value>.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.53</ci_lower_limit>
            <ci_upper_limit>.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Concurrent validity of the interviewer and self-administered versions of the TAPS Tool compared to the reference standard was assessed for Heroin Use Disorder using receiver operator characteristic (ROC) curves.</non_inferiority_desc>
            <param_type>Sensivity</param_type>
            <param_value>.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.53</ci_lower_limit>
            <ci_upper_limit>.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic and Statistical Manual DSM-5 Diagnosis of Tobacco Use Disorder Measured by the Modified World Mental Health Composite International Diagnostic Interview</title>
        <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
        <time_frame>Baseline</time_frame>
        <population>adult primary care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administration</title>
            <description>Interviewer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Tablet computer administration of a substance misuse screening instrument (TAPS Tool).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic and Statistical Manual DSM-5 Diagnosis of Tobacco Use Disorder Measured by the Modified World Mental Health Composite International Diagnostic Interview</title>
          <description>The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria</description>
          <population>adult primary care patients</population>
          <units>Sensivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".74" lower_limit=".69" upper_limit=".77"/>
                    <measurement group_id="O2" value=".73" lower_limit=".69" upper_limit=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Risk Tobacco Use Measured by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)</title>
        <description>The ASSIST assess lifetime and past 3 month substance use. A score on the Tobacco Scale from 0-3 is low risk, 4-26 is medium risk, and 27 or greater is high risk.The scales range is from 0 (no problem) to 31 (most severe problem).</description>
        <time_frame>Baseline</time_frame>
        <population>Adult primary care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administered</title>
            <description>Interviewer administration of TAPS Tool. The ASSIST was interviewer administered as well.</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Tablet computer administration of TAPS Tool. The ASSIST was administered in by an interview.</description>
          </group>
        </group_list>
        <measure>
          <title>High Risk Tobacco Use Measured by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)</title>
          <description>The ASSIST assess lifetime and past 3 month substance use. A score on the Tobacco Scale from 0-3 is low risk, 4-26 is medium risk, and 27 or greater is high risk.The scales range is from 0 (no problem) to 31 (most severe problem).</description>
          <population>Adult primary care patients</population>
          <units>Sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" lower_limit=".83" upper_limit=".94"/>
                    <measurement group_id="O2" value=".90" lower_limit=".83" upper_limit=".94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unhealthy Cannabis Use</title>
        <description>The Time Line Follow Back Interview measures participant's self-reported number of days of cannabis use in the 30 days prior to the interview. Unhealthy cannabis use is considered 1 or more days of cannabis use in the past 30 days.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administered</title>
            <description>Interviewer administered TAPS. The Time Line Follow Back was interviewer administered.</description>
          </group>
          <group group_id="O2">
            <title>Tablet Administration</title>
            <description>Tablet computer administration of TAPS Tool. The TLFB was interviewer administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Unhealthy Cannabis Use</title>
          <description>The Time Line Follow Back Interview measures participant's self-reported number of days of cannabis use in the 30 days prior to the interview. Unhealthy cannabis use is considered 1 or more days of cannabis use in the past 30 days.</description>
          <units>Sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".85" lower_limit=".82" upper_limit=".88"/>
                    <measurement group_id="O2" value=".84" lower_limit=".81" upper_limit=".88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risky Alcohol Use</title>
        <description>Measured by the Alcohol Use Disorders Identification Test - Consumption Items. High risk on the AUDIT-C is 10 or higher. The higher the score on the AUDIT-C the greater the alcohol problem.The range of scores on the AUDIT-C is from 0 (no problem) to 12 (maximum problem).</description>
        <time_frame>Baseline</time_frame>
        <population>Adult Primary Care Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Self-administered</title>
            <description>Self-administered TAPS Tool. The AUDIT-C was interviewer administered.</description>
          </group>
          <group group_id="O2">
            <title>Interviewer Administered</title>
            <description>Interviewer administered TAPS Tool. The AUDIT-C was interviewer administered for both group</description>
          </group>
        </group_list>
        <measure>
          <title>Risky Alcohol Use</title>
          <description>Measured by the Alcohol Use Disorders Identification Test - Consumption Items. High risk on the AUDIT-C is 10 or higher. The higher the score on the AUDIT-C the greater the alcohol problem.The range of scores on the AUDIT-C is from 0 (no problem) to 12 (maximum problem).</description>
          <population>Adult Primary Care Patients</population>
          <units>Spearman Correlation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".63" lower_limit=".59" upper_limit=".66"/>
                    <measurement group_id="O2" value=".64" lower_limit=".61" upper_limit=".68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The association on the interviewer and tablet computer administered versions of the TAPS Tool compared to the reference standard AUDIT-C score was assessed using Spearman Correlation.</non_inferiority_desc>
            <param_type>Spearman Correlation</param_type>
            <param_value>.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.59</ci_lower_limit>
            <ci_upper_limit>.66</ci_upper_limit>
            <estimate_desc>The estimated value is a Spearman Correlation point estimate between TAPS Tool Alcohol Score and the AUDIT-C score. A Confidence Interval rather than a dispersion value is therefore reported.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) was tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The association on the interviewer and tablet administered versions of the TAPS Tool compared to the reference standard of the AUDIT C score was assessed using Spearman Correlation.</non_inferiority_desc>
            <param_type>Spearman Correlation</param_type>
            <param_value>.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.61</ci_lower_limit>
            <ci_upper_limit>.68</ci_upper_limit>
            <estimate_desc>The estimated value is a Spearman Correlation point estimate between TAPS Tool Alcohol Score and the AUDIT-C Score. A Confidence Interval rather than a dispersion value is therefore reported.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cigarette Smoking Risk</title>
        <description>Measured by the Fagerstrom Test for Nicotine Dependence. The range of scores on the Fagerstrom Test if from 0 (no risk) to 10 (highest risk). High risk is considered a score of 6 or greater.</description>
        <time_frame>baseline</time_frame>
        <population>Adult Primary Care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Self-administered TAPS Tool</title>
            <description>Self-administered TAPS Tool. The Fagerstrom Test for Nicotine Dependence was administered by interviewer.</description>
          </group>
          <group group_id="O2">
            <title>Interviewer Administered</title>
            <description>Interviewer administered TAPS Tool. The Fagerstrom Test was interviewer administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Cigarette Smoking Risk</title>
          <description>Measured by the Fagerstrom Test for Nicotine Dependence. The range of scores on the Fagerstrom Test if from 0 (no risk) to 10 (highest risk). High risk is considered a score of 6 or greater.</description>
          <population>Adult Primary Care patients</population>
          <units>Spearman Correlation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".73" lower_limit=".70" upper_limit=".76"/>
                    <measurement group_id="O2" value=".75" lower_limit=".73" upper_limit=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smokeless Tobacco Questionnaire</title>
        <description>Any yes response to smokeless tobacco use reported on the smokeless tobacco questionnaire is considered high risk.</description>
        <time_frame>baseline</time_frame>
        <population>Adult Primary Care patients</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administered</title>
            <description>Interviewer administered TAPS Tool. The Smokeless Tobacco Questionnaire was interviewer administered.</description>
          </group>
          <group group_id="O2">
            <title>Self Administered</title>
            <description>Self-administered TAPS Tool. The Smokeless Tobacco Questionnaire was interviewer administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Smokeless Tobacco Questionnaire</title>
          <description>Any yes response to smokeless tobacco use reported on the smokeless tobacco questionnaire is considered high risk.</description>
          <population>Adult Primary Care patients</population>
          <units>Spearman Correlation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2000"/>
                <count group_id="O2" value="2000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".29" lower_limit=".25" upper_limit=".33"/>
                    <measurement group_id="O2" value=".28" lower_limit=".24" upper_limit=".32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet computer) was tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The association on the interviewer and tablet computer administered versions of the TAPS Tool compared to the reference standard Smokeless Tobacco Questionnaire was assessed using Spearman Correlation.</non_inferiority_desc>
            <param_type>Spearman Correlation</param_type>
            <param_value>.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.25</ci_lower_limit>
            <ci_upper_limit>.33</ci_upper_limit>
            <estimate_desc>The estimated value is a Spearman Correlation point estimate between the TAPS Tool Tobacco Score and the Smokeless Tobacco Questionnare. Confidence Interval rather than a dispersion value is therefore reported.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Spearman Correlation</param_type>
            <param_value>.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.24</ci_lower_limit>
            <ci_upper_limit>.32</ci_upper_limit>
            <estimate_desc>The estimated value is a Spearman Correlation point estimate between TAPS Tool Tobacco Score and the score on the Smokeless Tobacco Questionnaire. A Confidence Interval rather than a dispersion value is therefore reported.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cannabis Positive Oral Fluid Test</title>
        <description>Positive Oral Fluid Cannabis testing.</description>
        <time_frame>baseline</time_frame>
        <population>Adult Primary Care Patients with oral fluid test results</population>
        <group_list>
          <group group_id="O1">
            <title>Interviewer Administered</title>
            <description>Interviewer administered TAPS Tool. Oral Fluid Cannabis Test administered to the subset of participants that consented to provide an oral fluid sample. Oral fluid specimen was collected the same way in both arms.</description>
          </group>
          <group group_id="O2">
            <title>Self-administered TAPS Tool</title>
            <description>Self administered TAPS Tool. Oral Fluid Cannabis Test administered to the subset of participants that consented to provide an oral fluid sample. Oral fluid specimen was collected the same way in both arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Cannabis Positive Oral Fluid Test</title>
          <description>Positive Oral Fluid Cannabis testing.</description>
          <population>Adult Primary Care Patients with oral fluid test results</population>
          <units>Spearman Correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1802"/>
                <count group_id="O2" value="1802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".42"/>
                    <measurement group_id="O2" value=".40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each administration approach (interviewer and tablet) were tested separately against the reference measure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The association on the interviewer and tablet computer administered versions of the TAPS Tool compared to the reference standard of the results of the oral fluid test was assessed using Spearman Correlation.</non_inferiority_desc>
            <param_type>Spearman Correlation</param_type>
            <param_value>.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.35</ci_lower_limit>
            <ci_upper_limit>.48</ci_upper_limit>
            <estimate_desc>The estimated value is a Spearman Correlation point estimate between TAPS Tool Cannabis Score and the results of the Oral Fluid Test. Confidence Interval rather than a dispersion value is therefore reported.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Spearman Correlation</param_type>
            <param_value>.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.33</ci_lower_limit>
            <ci_upper_limit>.46</ci_upper_limit>
            <estimate_desc>The estimated value is a point estimate of the Spearman Correlation between the TAPS Tool Cannabis Score and the Oral Fluid Cannabis Screen. A Confidence Interval rather than a dispersion value is therefore reported.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline data only gathered in this study.</time_frame>
      <desc>The all cause mortality and serious adverse event data refer to the total combined sample (n = 2,000). We report the total sample here because all participants received both the interviewer and self-administered versions one immediately after the other in one single session.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants enrolled in the study (because all participants were administered both the self-administered and the interviewer administered versions of the instrument, we are reporting adverse events for the total sample)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2000"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Blood on oral swab</sub_title>
                <description>Traces of blood were seen on oral swab</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="2000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Schwartz</name_or_title>
      <organization>Friends Research Institute</organization>
      <phone>410-837-3977 ext 276</phone>
      <email>rschwartz@friendsresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

